125 I粒子植入联合盐酸安罗替尼治疗晚期非小细胞肺癌的临床疗效观察  

Clinical observation of 125 I seed implantation combined with amlotinib hydrochloride in the treatment of advanced non-small cell lung cancer

作　　者：严一杰 张军[1] 王硕[1] 孟繁杰 王斌[1] 关志宇[1] Yan Yijie;Zhang Jun;Wang Shuo;Meng Fanjie;Wang Bin;Guan Zhiyu(Department of Thoracic Surgery,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院胸外科,300211

出　　处：《国际生物医学工程杂志》2021年第4期277-280,285,共5页International Journal of Biomedical Engineering

摘　　要：目的探讨125 I粒子植入联合盐酸安罗替尼在非小细胞肺癌(NSCLC)治疗中的临床疗效。方法纳入61例NSCLC患者,其中30例(观察组)接受125 I粒子植入联合安罗替尼治疗,31例(对照组)只接受125 I粒子植入治疗。评价所有患者的疗效和不良反应,同时测定两组患者治疗前及治疗第1、3月后,外周血中癌胚抗原(CEA)、细胞角蛋19片段(CYFRA21-1)、神经内分泌烯醇酶(NSE)、鳞状细胞癌抗原(SCC)以及疗效情况。结果观察组治疗后1月和3月的有效率分别为90.00%、93.33%;对照组治疗后1月和3月的有效率分别为67.74%、74.19%,两组间的差异有统计学意义(χ^(2)=4.504,P=0.034;χ^(2)=4.075,P=0.044)。治疗后两组患者的不良反应发生率差异无统计学意义(P=0.785)。治疗后1月和3月,两组患者外周血中CEA、CYFRA21-1、NSE和SCC水平均低于治疗前(均P<0.05)。结论125 I粒子植入联合盐酸安罗替尼治疗晚期非小细胞肺癌是安全的,具有推广价值。Objective To investigate the clinical efficacy of 125 I seed implantation combined with anlotinib hydrochloride in the treatment of non-small cell lung cancer(NSCLC).Methods 61 cases of NSCLC patients were enrolled,of which 30 cases(observation group)received 125 I seed implantation combined with anlotinib treatment,and 31 cases(control group)received 125 I seed implantation only.To evaluate the curative effect and adverse reactions of all patients,the carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),neuroendocrine enolase(NSE),squamous cell carcinoma antigen(SCC)in the peripheral blood of the two groups was measured before the treatment and at 1 and 3 months after the treatment.Results The effective rates in the observation group were 90.00%and 93.33%,the effective rates in the control group were 67.74%and 74.19%at 1 and 3 months after the treatment,respectively,and the difference in efficacy between the two groups was statistically significant(χ^(2)=4.504,P=0.034 vs.χ^(2)=4.075,P=0.044).There was no significant difference in the incidence of adverse reactions between the two groups of patients after treatment(P=0.785).At 1 and 3 months after the treatment,the levels of CEA,CYFRA21-1,NSE and SCC in the peripheral blood of the two groups of patients were lower than those before the treatment(all P<0.05).Conclusions 125 I seed implantation combined with anlotinib hydrochloride is safe for the treatment of advanced non-small cell lung cancer,and has promotion value.

关 键 词：非小细胞肺癌 125 I粒子植入 盐酸安罗替尼 

分 类 号：R734.2[医药卫生—肿瘤]